Having trouble accessing articles? Reset your cache.

Feb. 5 Financial Quick Takes: Aimmune gets $200M Nestlé investment; plus Vineti, MaaT, Kezar, Ziopharm, Ikarovec

$200M for Aimmune as it expands allergy pipeline
Nestlé Health Science made a $200 million equity investment in Aimmune Therapeutics Inc. (NASDAQ:AIMT), giving it a 19.9% stake in the allergy company based on its outstanding common shares. Also on Wednesday, Aimmune licensed exclusive,

Read the full 423 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE